4th Annual Forum on

Pharma Patents

The Legal and Strategic Guide

Tuesday, October 18, 2005

About

There are many challenges facing the pharmaceutical industry today. It is absolutely critical to keep up-to-date with the rapid pace of complex legal and regulatory developments in pharma patents to maintain a competitive edge. Millions of dollars are at stake. Brand name companies stand to lose if their pharma patents are inadequately protected. Generics want to benefit from early market entry of non-infringing drugs, challenging potentially invalid patents. Competition between generics and brand names is heating up and the stakes are high.

This Canadian Institute publication on Pharma Patents will arm you with cutting-edge strategies and practical legal skills to help you to meet the challenges of the complex world of pharma patents. You'll learn from experienced industry lawyers, in-house counsel and pharma executives on important topics including:
  • The latest proposed amendments to the critical PM (NOC) Regulations
  • Effect of proposed pricing changes and increased data protection
  • Crucial legal developments in patent filings: what you need to know
  • Key developments in United States patent law and their effect on Canadian companies

Contents & Contributors

About

There are many challenges facing the pharmaceutical industry today. It is absolutely critical to keep up-to-date with the rapid pace of complex legal and regulatory developments in pharma patents to maintain a competitive edge. Millions of dollars are at stake. Brand name companies stand to lose if their pharma patents are inadequately protected. Generics want to benefit from early market entry of non-infringing drugs, challenging potentially invalid patents. Competition between generics and brand names is heating up and the stakes are high.

This Canadian Institute publication on Pharma Patents will arm you with cutting-edge strategies and practical legal skills to help you to meet the challenges of the complex world of pharma patents. You'll learn from experienced industry lawyers, in-house counsel and pharma executives on important topics including:
  • The latest proposed amendments to the critical PM (NOC) Regulations
  • Effect of proposed pricing changes and increased data protection
  • Crucial legal developments in patent filings: what you need to know
  • Key developments in United States patent law and their effect on Canadian companies

Contents & Contributors


AMENDMENTS TO THE PATENTED MEDICINES (NOTICE OF COMPLIANCE) REGULATIONS STATUS UPDATE
Douglas Clark, Industry Canada

UPDATE ON PROPOSED AMENDMENTS TO THE PATENTED MEDICINES (NOTICE OF COMPLIANCE) REGULATIONS AND THE FOOD AND DRUG REGULATIONS
Edward Hore, Hazzard & Hore

THE BIOLYSE DECISION: IMPLICATION OF A NEW INTERPRETATIVE APPROACH TO THE NOC REGULATIONS
Barbara J. Murchie, Bennett Jones LLP
Paul Taylor, Bennett Jones LLP

CRITICAL DEVELOPMENTS IN PHARMA PATENT CASE LAW THIS YEAR
Ken Clark, Gowling Lafleur Henderson LLP
Neil Belmore, Gowling Lafleur Henderson LLP
Taren Wilkins, Gowling Lafleur Henderson LLP
Roger Tam, Gowling Lafleur Henderson LLP

RECENT JURISPRUDENCE UNDER THE NOC REGULATIONS
Gunars A. Gaikis, Smart & Biggar
Junyi Chen, Smart & Biggar

PHARMA PATENTS FORUM: THE GENERICS VIEW
Jim Keon, Canadian Generic Pharmaceutical Association

PROVINCIAL FORMULARIES AND PHARMA PATENTS
Julia Brown, Janssen Ortho Inc.
Megan Evans, Cassels Brock & Blackwell LLP

PROPOSED CHANGES TO PRICING: UPDATE ON PMPRB PRICE CONTROLS
Barbara L. Ouellet, Patented Medicine Prices Review Board

RECENT U.S. PATENT DEVELOPMENTS: WHAT THEY MEAN FOR CANADIAN PHARMA
James Leeds, Eli Lilly & Company

RECENT U.S. PATENT DEVELOPMENTS: A CANADIAN PERSPECTIVE
Ildiko Mehes, Novopharm

RECENT U.S. PATENT DEVELOPMENTS: A CANADIAN PERSPECTIVE
Shonagh McVean, Gilbert's LLP

RECENT U.S. PATENT DEVELOPMENTS: WHAT THEY MEAN FOR CANADIAN PHARMA
James F. Haley, Jr., Ropes & Gray

WHEN THE ELEPHANT CATCHES COLD: CANADIAN DRUG SUPPLY REGULATION IN THE FACE OF U.S. INTERNET DEMAND AND POTENTIAL U.S. BULK IMPORT LEGISLATION
John A. Terry, Torys LLP

DRUG IMPORTATION: OPENING THE FLOODGATES FOR FAKE DRUGS?
Timothy H. Gilbert, Gilbert's LLP

INTERNATIONAL PRESCRIPTION SERVICES: AN EVOLVING LANDSCAPE
John A. Myers, Taylor McCaffrey LLP

PM (NOC) REGULATIONS & PATENT LIST ELIGIBILITY: THE MEANING OF "CLAIM FOR THE MEDICINE ITSELF"
Jason C. Markwell, Ogilvy Renault

MIXIMIZING YOUR PHARMA PATENT PROTECTION
Yoon Kang, Smart & Biggar
Nancy P. Pei, Smart & Biggar



DOCUMENT TYPES: PRESENTATIONS AVAILABLE: 0